Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

The firm then sold three of Catalent's plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.

The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing ... to stop using the plants to produce ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced ...